| Tumor characteristics |
Kynurenine (µ mol/L) |
Kyn/Trp |
| |
Mean ± SD |
p |
Mean ± SD |
p |
| T* |
| T1 |
1.95[1.36;2.45] |
0.332 |
0.045 [0.035; 0.053] |
0.770 |
| T2 |
1.55[1.10; 1.78] |
|
0.05[0.04; 0.06] |
|
| T3 |
1.75[1.43; 2.10] |
|
0.05[0.04; 0.06] |
|
| T4 |
1.55[1.40; 1.90] |
|
0.05[0.04;0.07] |
|
| N* |
|
|
|
|
| N0 |
1.7 [1.4; 2.1] |
0.447 |
0.05[0.04;0.06] |
0.500 |
| N1 |
1.6 [1.1; 1.8] |
|
0.04[0.04;0.07] |
|
| N2 |
1.8 [1.5; 2] |
|
0.05[0.045;0.065] |
|
| M° |
| M0 |
1.7[1.4;2.1] |
0.654 |
0.05[0.04; 0.06] |
0.709 |
| M1 |
1.75[1.23; 1.9] |
|
0.045[0.04; 0.068] |
|
| VELIPI |
| Vascular emboli° |
1.8[1.18; 2.13] |
0.966 |
0.04[0.04;0.075] |
0.895 |
| Lymphatic invasion° |
1.7[1.4; 2.1] |
0.995 |
0.05[0.04; 0.06] |
0.805 |
| Perineural invasion° |
1.6[1.43; 2.05] |
0.905 |
0.05[0.04; 0.058] |
0.698 |
| MSI-H° |
1.7[1.6; 1.7] |
0.745 |
0.04[0.04; 0.05] |
0.336 |
| Stenosis° |
1.7[1.4; 1.9] |
0.8822 |
0.05[0.04; 0.07] |
0.719 |
|
|
Continuous data are expressed as median [first quartile; third quartile]
*Kruskal-Wallis rank sum test
°Wilcoxon rank sum test |
| Table 3: Association between tumor characteristics and activation of tryptophan metabolism in patients with CRC. |
